Vitex, Baxter Target West Nile Virus With Red Blood Cell Screening Systems
This article was originally published in The Gray Sheet
Executive Summary
West Nile Virus is one of the pathogens for which Baxter/Cerus and Vitex plan to market the red blood cell inactivation systems Intercept and Inactine, respectively